{"preliminary_commentary":{"by_channel":{"x_thread":4},"note":"Preliminary. Indexed podcasts, YouTube videos and posts on X and Bluesky that name this trial so far. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":null,"indication":null,"name":"NCT06038396","nct_id":"NCT06038396","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct06038396. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Participants receive RC118- ADC(dose A or dose B) Q2W and Toripalimab (fixed dose) Q3W","label":"Part A-RC118 plus Toripalimab","type":"EXPERIMENTAL"},{"description":"Referring to the results of the Part A, an extension cohort using RC118 plus Toripalimab /RC148 will be established.","label":"Part B-RC118 plus Toripalimab / RC148","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2026-08-31","type":"ESTIMATED"},"conditions":["Advanced Solid Tumor"],"enrollment":{"count":48,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"RC118","otherNames":["RC118 for injection"],"type":"DRUG"},{"name":"Toripalimab","otherNames":["Toripalimab injection","JS001"],"type":"DRUG"},{"name":"RC148","otherNames":[],"type":"DRUG"}],"last_update":"2025-01-29","lead_sponsor":"RemeGen Co., Ltd.","official_title":"A Phase I/II Clinical Study to Evaluate the Safety and Efficacy of RC118 in Combination with Toripalimab / RC148 for Patients with Claudin 18.2-Positive, Locally Advanced Unresectable or Metastatic Malignant Solid Tumors","overall_status":"UNKNOWN","phases":["PHASE1","PHASE2"],"primary_completion_date":{"date":"2026-02-28","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Phase1: Dose limiting toxicity (DLT)","timeFrame":"The first 3 weeks (21 days) after the start of dosing at each dose level"},{"measure":"Phase1/2: Adverse events (AEs)","timeFrame":"[Time Frame: 15 months]"},{"measure":"Phase1: Maximum tolerated dose(MTD)","timeFrame":"up to 12 months"},{"measure":"Phase1: Recommended Phase 2 Dose (RP2D)","timeFrame":"up to 12 months"},{"measure":"Phase 2: Objective response rate (ORR)","timeFrame":"15 months"}],"references":[],"start_date":{"date":"2023-08-03","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of RC118 Plus Toripalimab / RC148 in Patients with Locally Advanced Unresectable or Metastatic Solid Tumors","url":"https://clinicaltrials.gov/study/NCT06038396"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.3","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct06038396"}